IRIS - Institutional Research Information System
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi dell’Insubria.

IRInSubria - Institutional Repository Insubria
IRInSubria raccoglie, conserva, documenta e dissemina le informazioni sulla produzione scientifica dell'Università degli Studi dell’Insubria anche ai fini della valutazione della ricerca.

AGENO, WALTER
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 49.249
EU - Europa 24.053
AS - Asia 13.326
SA - Sud America 1.894
AF - Africa 161
Continente sconosciuto - Info sul continente non disponibili 56
OC - Oceania 25
Totale 88.764
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 48.877
IT - Italia 11.644
SG - Singapore 4.427
UA - Ucraina 4.090
TR - Turchia 2.831
HK - Hong Kong 1.887
SE - Svezia 1.841
DE - Germania 1.780
VN - Vietnam 1.754
CN - Cina 1.743
BR - Brasile 1.622
IE - Irlanda 1.233
GB - Regno Unito 944
RU - Federazione Russa 843
FI - Finlandia 820
FR - Francia 307
IN - India 191
CA - Canada 184
MX - Messico 146
BD - Bangladesh 113
AT - Austria 104
AR - Argentina 95
JP - Giappone 83
NL - Olanda 82
PL - Polonia 78
ES - Italia 73
ZA - Sudafrica 65
IQ - Iraq 58
EU - Europa 53
EC - Ecuador 46
BE - Belgio 44
CZ - Repubblica Ceca 34
CO - Colombia 31
LT - Lituania 29
VE - Venezuela 27
SA - Arabia Saudita 26
UZ - Uzbekistan 25
ID - Indonesia 23
MA - Marocco 23
PK - Pakistan 23
CL - Cile 22
AE - Emirati Arabi Uniti 21
AU - Australia 19
PY - Paraguay 19
CH - Svizzera 18
DZ - Algeria 15
KE - Kenya 15
UY - Uruguay 15
MY - Malesia 14
JO - Giordania 13
PT - Portogallo 13
EG - Egitto 12
RO - Romania 11
GR - Grecia 9
IL - Israele 9
BO - Bolivia 8
IR - Iran 8
TN - Tunisia 8
CR - Costa Rica 7
DK - Danimarca 7
KR - Corea 7
LB - Libano 7
MK - Macedonia 7
PE - Perù 7
PS - Palestinian Territory 7
TT - Trinidad e Tobago 7
TW - Taiwan 7
BG - Bulgaria 6
HU - Ungheria 6
NP - Nepal 6
AL - Albania 5
JM - Giamaica 5
KZ - Kazakistan 5
NZ - Nuova Zelanda 5
OM - Oman 5
RS - Serbia 5
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
CI - Costa d'Avorio 4
ET - Etiopia 4
LK - Sri Lanka 4
NG - Nigeria 4
BB - Barbados 3
BN - Brunei Darussalam 3
BS - Bahamas 3
DO - Repubblica Dominicana 3
GE - Georgia 3
GT - Guatemala 3
HN - Honduras 3
HR - Croazia 3
KW - Kuwait 3
PH - Filippine 3
SN - Senegal 3
AM - Armenia 2
AO - Angola 2
BY - Bielorussia 2
EE - Estonia 2
KH - Cambogia 2
LI - Liechtenstein 2
LY - Libia 2
Totale 88.730
Salva come PNG Salva come JPEG
Città #
Milan 8.497
Fairfield 7.198
Woodbridge 4.799
Ashburn 4.014
Houston 3.549
Jacksonville 3.302
Seattle 2.800
Wilmington 2.630
Cambridge 2.459
Ann Arbor 2.425
Singapore 2.330
Chandler 2.236
Hong Kong 1.877
Dallas 1.539
Izmir 1.395
Princeton 1.350
Dublin 1.224
Dearborn 961
Boardman 830
Dong Ket 683
Nyköping 664
Rome 627
The Dalles 536
Beijing 507
Chicago 421
San Diego 398
Los Angeles 314
San Mateo 308
Ogden 261
New York 255
London 248
Como 190
Santa Clara 169
Washington 164
São Paulo 160
Munich 153
Ho Chi Minh City 141
Düsseldorf 139
Hefei 126
Redmond 122
Nanjing 98
Kocaeli 88
Nuremberg 83
Kunming 82
Verona 81
Mexico City 80
Tokyo 76
Hanoi 75
Norwalk 75
Helsinki 74
Warsaw 66
Phoenix 64
Salt Lake City 64
Montreal 61
Buffalo 60
Guangzhou 59
Brooklyn 57
Nanchang 57
San Francisco 55
Turku 55
Council Bluffs 52
Jinan 52
Rio de Janeiro 52
Stockholm 51
Columbus 49
Boston 47
Chennai 47
Tampa 47
Toronto 47
Frankfurt am Main 46
Belo Horizonte 45
Atlanta 42
Denver 42
Vienna 42
Johannesburg 39
Kilburn 39
Falls Church 38
Brussels 37
Elk Grove Village 37
Amsterdam 36
Philadelphia 36
Orem 34
Besana In Brianza 33
Fuzhou 30
Brno 28
Curitiba 28
Prescot 27
Shanghai 27
Poplar 26
Redwood City 26
Zhengzhou 26
Chiswick 25
Detroit 25
Manchester 25
Berlin 23
Miami 22
Shenyang 22
Tashkent 22
Ankara 21
Brasília 21
Totale 64.825
Salva come PNG Salva come JPEG
Nome #
Establishing diagnostic criteria and treatment of subsegmental pulmonary embolism: a Delphi analysis of experts 390
A survey of thrombosis prophylaxis use in patients undergoing arthroscopic surgery 292
Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes 290
A clinical score to rule out the concomitant presence of deep vein thrombosis in patients presenting with superficial vein thrombosis: The ICARO study 278
Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study 275
Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis 259
A case report and literature review of portal vein thrombosis associated with Cytomegalovirus infection in immunocompetent patients 251
Effect of Vitamin K Intake on the Stability of Treatment with Vitamin K Antagonists: A Systematic Review of the Literature 247
Oral anticoagulant therapy in patients with mechanical heart valve and intracranial haemorrhage. A systematic review 245
Abdominal obesity and the risk of recurrent deep vein thrombosis 245
Risk of recurrence of unusual site venous thromboembolism 231
Clinical history and antithrombotic treatment of incidentally detected splanchnic vein thrombosis: a multicentre, international prospective registry 231
Risk factors for suboptimal efficacy of 3-factor prothrombin complex concentrates in emergency vka anticoagulation reversal 231
Relationship between regulatory T cells subsets and lipid profile in dyslipidemic patients: A longitudinal study during atorvastatin treatment 231
2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism 230
Breadth of complications of long-term oral anticoagulant care 228
Management of recurrent venous thromboembolism in cancer patients 227
Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry. 226
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature 226
ABO blood group and vascular disease: an update 225
incidence of thromboembolic complications in patients with mechanical heart valves with a subtherapeutic international normalized ratio. 223
Optimal treatment duration of venous thrombosis 220
Prevention and treatment of venous thromboembolism 217
Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients 215
Incidence rates and case fatality rates of portal vein thrombosis and Budd-Chiari Syndrome 214
Diagnostic accuracy of lung ultrasound for pulmonary embolism: a systematic review and meta-analysis. 213
A new era for venous thromboembolism prevention in medical inpatients 212
Venous ischemic syndromes 212
Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy 211
Exaggerated initial response to warfarin following heart valve replacement 210
Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study 210
Brain natriuretic peptide as a preclinical marker of chronic pulmonary hypertension in patients with pulmonary embolism. 210
Pulmonary Embolism Severity Index Accurately Predicts Long-Term Mortality Rate In Patients Hospitalized For Acute Pulmonary Embolism 210
Unsuspected pulmonary embolism in cancer patients: a narrative review with pooled data 209
A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program. 208
Association between ABCG2 and ABCB1 genes and warfarin stability: a case-control study 208
The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry 208
A comparative study using thrombin generation and three different INR methods in patients on Vitamin K antagonist treatment 207
Patient selection for thromboprophylaxis in medical inpatients 205
Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy: A randomized, controlled trial 204
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty 202
Role of ABO blood group and of other risk factors on the presence of residual vein obstruction after deep-vein thrombosis 202
Diagnosis and management of venous thromboembolism: Results of a survey on current clinical practice 202
A randomized comparison of a computer-based dosing program with a manual system to monitor oral anticoagulant therapy. 199
Warfarin interactions with antibiotics in the ambulatory care setting 199
Effect of thromboprophylaxis with anticoagulant drugs on the incidence of arterial thrombotic events in medical inpatients: a systematic review 199
Metabolic syndrome and hyperhomocysteinemia in patients with deep vein thrombosis: a case-control study 198
Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants 197
Venous thromboembolism: “…an ounce of prevention is worth a pound of cure” 197
Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: A multicenter cohort study 197
Major Bleeding and Case Fatality Rate with the Direct Oral Anticoagulants in Orthopedic Surgery: A Systematic Review and Meta-Analysis 196
Incidence of chronic pulmonary hypertension in patients with previous pulmonary embolism 195
Prevalence and Clinical History of Incidental, Asymptomatic Pulmonary Embolism: A Meta-Analysis 195
Recurrent Thrombotic Events after Discontinuation of Vitamin K Antagonist Treatment for Splanchnic Vein Thrombosis: A Multicenter Retrospective Cohort Study 194
Oral rivaroxaban for symptomatic venous thromboembolism 193
A commentary: to screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry. 193
Venous and arterial thrombosis in patients with HIV infection 193
Prognostic stratification of chronic heart failure in elderly population: are cardiopulmonary tests and BNP really valuable? 193
Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): An international, prospective, non-interventional study 193
Applying EBM in clinical practice 191
A survey of thromboprophylaxis management in patients with major trauma. 191
Management of incidental splanchnic vein thrombosis in cancer patients 191
Real-world economic burden of venous thromboembolism and antithrombotic prophylaxis in medical inpatients 190
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis 189
Abdominal obesity and the risk of recurrent deep vein thrombosis. 189
Venous thromboembolism: Past, present and future 189
Pulmonary embolism prognostic factors and length of hospital stay: A cohort study 189
Adverse events associated with the use of direct-acting oral anticoagulants in clinical practice: Beyond bleeding complications 189
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation 188
Predictors of residual venous obstruction after deep vein thrombosis of the lower limbs: a prospective cohort study 187
Treating patients with cancer and acute venous thromboembolism 187
Non-vitamin K oral anticoagulants in patients with pulmonary embolism: a systematic review and meta-analysis of the literature 187
Prevention and treatment of venous thromboembolism in patients with solid brain neoplasms: results of a survey among Italian physicians 187
Atypical case of Acute Coronary Syndrome due to Coronary-Pulmonary Steal Syndrome secondary to Pulmonary Embolism. 186
Timing of anticoagulation therapy in patients with acute ischaemic stroke and atrial fibrillation 186
Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy 185
Anticoagulant therapy for venous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature: a reply to a rebuttal 184
Duration of anticoagulation after venous thromboembolism in real world clinical practice 184
Presence of residual thromboemboli at least six months after a first episode of symptomatic pulmonary embolism: do perfusion scintigraphy and angio-computed tomography agree? 183
Anticoagulation After Stroke in Patients With Atrial Fibrillation: To Bridge or Not With Low-Molecular-Weight Heparin? 183
Statins and secondary prevention of ischemic and hemorrhagic stroke 182
Acute myeloid leukemia with associated translocation t(15;17) and 11q23/MLL abnormality 182
Guidance for the management of venous thrombosis in unusual sites 182
Statin use and bleeding risk during vitamin K antagonist treatment for venous thromboembolism: A multicenter retrospective cohort study 182
Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study 182
Update on the diagnosis and management of pulmonary embolism 182
Direct oral anticoagulants in rare venous thrombosis 181
Diagnostic accuracy of magnetic resonance imaging in patients with suspected pulmonary embolism: A bivariate meta-analysis 181
Managing challenging patients with venous thromboembolism: A practical, case-based approach 181
Perioperative anticoagulation for patients with mechanical heart valves: a survey of current practice. 180
24-hour blood pressare profile and left ventricular anatomy and function in untreated hypertensives with and without microalbuminuria 180
Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis. The ”CANCER DACUS” study 180
The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE 179
When and how to use antidotes for the reversal of direct oral anticoagulants: Guidance from the SSC of the ISTH 179
Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism: An analysis of the randomised, double-blind HOKUSAI VTE trial 178
Prediction of Early Recurrent Thromboembolic Event and Major Bleeding in Patients With Acute Stroke and Atrial Fibrillation by a Risk Stratification Schema: The ALESSA Score Study 178
Antidotes for the direct oral anticoagulants: What news? 178
The role of inherited thrombophilia in patients with isolated pulmonary embolism: a systematic review and a meta-analysis of the literature 177
Gender Difference in Efficacy and Safety of Nonvitamin K Antagonist Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation or Venous Thromboembolism: A Systematic Review and a Meta-Analysis of the Literature 177
Statins for acute ischemic stroke 177
Totale 20.554
Salva come PNG Salva come JPEG
Categoria #
all - tutte 392.712
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 392.712
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20218.021 0 0 0 0 0 1.396 543 1.226 1.503 803 953 1.597
2021/20226.828 757 872 355 182 402 376 337 375 386 1.267 644 875
2022/20236.740 824 258 431 650 510 1.571 19 787 1.024 268 191 207
2023/202413.559 2.152 2.188 2.195 2.612 2.767 824 95 147 391 79 37 72
2024/20259.742 69 75 1.781 238 230 684 403 654 1.099 820 967 2.722
2025/20269.313 1.428 1.409 1.478 2.721 1.762 515 0 0 0 0 0 0
Totale 89.656